Agenus Revenue 2006-2021 | AGEN

Agenus revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Agenus Annual Revenue
(Millions of US $)
2020 $88
2019 $150
2018 $37
2017 $43
2016 $23
2015 $25
2014 $7
2013 $3
2012 $16
2011 $3
2010 $3
2009 $3
2008 $3
2007 $6
2006 $1
2005 $1
Agenus Quarterly Revenue
(Millions of US $)
2021-06-30 $11
2021-03-31 $12
2020-12-31 $31
2020-09-30 $15
2020-06-30 $27
2020-03-31 $15
2019-12-31 $35
2019-09-30 $20
2019-06-30 $16
2019-03-31 $80
2018-12-31 $6
2018-09-30 $13
2018-06-30 $16
2018-03-31 $2
2017-12-31 $8
2017-09-30 $3
2017-06-30 $4
2017-03-31 $27
2016-12-31 $6
2016-09-30 $4
2016-06-30 $7
2016-03-31 $6
2015-12-31 $8
2015-09-30 $7
2015-06-30 $6
2015-03-31 $4
2014-12-31 $2
2014-09-30 $2
2014-06-30 $3
2014-03-31 $1
2013-12-31 $0
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $13
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
2008-12-31 $1
2008-09-30 $1
2008-06-30 $1
2008-03-31 $1
2007-12-31 $1
2007-09-30 $1
2007-06-30 $1
2007-03-31 $2
2006-12-31 $0
2006-09-30 $0
2006-06-30 $0
2006-03-31 $0
2005-12-31 $0
2005-09-30 $0
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.375B $0.088B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29